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Abstract
Background and Aims: Having a body mass index above or equal to 30 kg/m
2 in conjunction with chronic hepatitis C virus
infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the
mechanisms whereby obesity reduces the efficacy of therapy remain unclear.
Methods: This study evaluated impact of obesity on outcome as well as interferon and ribavirin concentrations following
standard-of-care fixed dosing with peginterferon-a2a 180 mg once weekly and ribavirin 800 mg daily among 303 HCV
genotype 2/3-infected patients enrolled in the per-protocol analysis of a recently completed phase III trial (NORDynamIC).
Results: Patients with BMI $30 kg/m
2 showed poorer outcome following 24 weeks of therapy (SVR 62% vs. 89% for BMI
$30 vs. ,30; P=0.006) along with significantly higher steatosis grade (P=0.002), HOMA-IR (P,0.0001), triglyceride levels
(P=0.0002), and baseline viral load (P=0.028). Obesity was also significantly associated with lower plasma interferon
concentrations on days 3, 7, and 29 (P=0.02, P=0.0017, and P,0.0001, respectively) and lower plasma ribavirin
concentrations day 29 (P=0.025), and lower concentration of interferon in turn was associated with a poorer first phase
reduction in HCV RNA (P,0.0001). In multivariate analysis, ribavirin concentrations week 12, interferon concentrations day
29, and baseline HCV RNA levels were independent predictors of achieving SVR among patients treated for 24 weeks
(n=140).
Conclusions: Reduced bioavailability of interferon and ribavirin along with higher baseline viral load are dominant risk
factors for treatment failure in obese patients with chronic hepatitis C.
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Introduction
Hepatitis C virus (HCV) is the foremost cause of parenterally
transmitted hepatitis [1,2], and chronic infection is associated with
liver fibrosis, cirrhosis, and hepatocellular carcinoma [3,4].
Treatment with pegylated interferon-a and ribavirin yields
sustained viral response (SVR) rates of 50–80% [5,6,7], with
higher SVR rates seen in patients infected with HCV of genotypes
2 and 3.
Thirty percent of American adults are obese, i.e. have a body
mass index (BMI) above or equal to 30 kg/m
2 [8]. High BMI in
conjunction with HCV is associated with steatosis in HCV
genotype non-3 [9], increased fibrosis progression [10], and non-
responsiveness to antiviral treatment [11,12]. Details regarding the
mechanisms whereby obesity reduces the efficacy of combination
therapy, however, remain unclear. It has been hypothesized that
high BMI induces: (i) the metabolic syndrome leading to insulin
resistance, hepatic steatosis, and higher baseline viral load [13], (ii)
altered cytokine signaling as manifested by elevated levels of leptin,
adiponectin, and resistin [14], and (iii) reduced bioavailability of
interferon-a [15]. The aim of this study was to identify
independent risk factors for treatment failure among obese
patients who participated in a phase III trial (NORDynamIC;
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in chronic HCV genotype 2 and 3 infection.
Materials and Methods
The NORDynamIC trial
Three hundred and eighty-two treatment naı ¨ve patients with
HCV genotype 2/3 infection were randomized at baseline to
either 12 or 24 weeks of combination treatment with peginter-
feron-a2a 180 mg once weekly and ribavirin 800 mg daily. The
first dose of study medication was administered under the
supervision of a study nurse, and a patient diary monitored
subsequent dosing. Because plasma concentrations of peginter-
feron-a2a and ribavirin were analyzed and in order to minimize
the impact of adherence, patients constituting the per-protocol
population (i.e. having received at least 80% of the target dose of
peginterferon-a2a as well as at least 80% of the target dose of
ribavirin for at least 80% of the target treatment duration) were
included. Of 303 eligible patients, a body mass index could be
calculated for 300, and these latter patients were included in the
present study (baseline characteristics in Table 1). Further details
regarding this trial are provided elsewhere [16].
Classification of response
Patients were classified as achieving SVR if plasma HCV RNA
was undetectable (i.e. ,15 IU/mL) 24 weeks after completion of
therapy, as having relapsed if plasma HCV RNA was undetectable
at end-of-treatment but detectable 24 weeks after completion of
therapy, and as being non-responders if plasma HCV RNA was
detectable at end-of-treatment. Patients were classified as having a
rapid virological response (RVR) if HCV RNA was undetectable
day 29 and a complete early virological response (cEVR) if HCV
RNA was undetectable week 12.
HCV-RNA quantification
Plasma was obtained using PPT-tubes and HCV-RNA was
determined by RT-PCR of plasma using Cobas AmpliPrep/
COBAS TaqMan HCV Test (Roche Diagnostics, Branchburg,
NJ), which quantifies HCV-RNA with a limit of detection of
#15 IU/mL. HCV-RNA quantification was performed on days 0,
3, 7, 8, 29, week 8, week 12, week 24 (for those receiving 24 weeks
of therapy), and 24 weeks after completion of therapy. All samples
were frozen (270uC), and subsequently analyzed at the central
laboratory.
Table 1. Baseline Characteristics of the Patients Grouped by BMI (Per-Protocol Analysis).
BMI ,30 kg/m
2 BMI $30 kg/m
2
P
Characteristic (n=258) (n=42)
Gender
Male
a 158 (61%) 26 (63%) 0.8
d
Female
a 100 (39%) 15 (37%)
Age (years)
b 41.0 42.7 0.3
e
Route of transmission
a
Intravenous drug use 187 (72%) 32 (73%) 0.75
d
Transfusion 18 (7%) 4 (10%)
Health care worker 7 (3%) 0
Sexual 11 (4%) 1 (2%)
Unkown 35 (14%) 4 (10%)
Genotype 2 75 (29%) 15 (37%) 0.24
d
Genotype 3 184 (71%) 27 (66%)
Fibrosis Stage (Ishak score 0/1/2/3/4/5/6) 10/34/76/58/35/11/17 0/5/11/14/2/4/2 0.2
d
Steatosis Grade (0/1/2/3) 95/88/38/20 5/14/12/7 0.002
d
Log10 HCV-RNA (IU/mL)
b 6.04 6.34 0.028
e
IL28B SNP polymorphism
(rs12979860 CC/CT/TT) 111/108/28 18/19/3 0.75
d
Race
a (Caucasian/Asian/Black/Other) 243/6/1/8 42/0/0/0 0.46
d
Cholesterol (mmol/L)
b 4.1 (1.1) 4.4 (1.0) 0.9
e
Triglyceride (mmol/L)
b 1.0 (0.6) 1.5 (1.0) 0.0002
e
Systolic Blood Pressure (mm Hg)
b 126 (15) 138 (20) 0.0004
e
Diastolic Blood Pressure (mm Hg)
b 78 (10) 85 (12) 0.002
e
Alcohol Consumption (units/week)
c 0.25 (0–18) 1 (0–30) 0.84
e
aNo. (%);
bMean (SD);
cMedian (Range);
dChi square test,
eMann-Whitney U-test; two patients were infected with both genotype 2 and 3.
doi:10.1371/journal.pone.0037521.t001
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(HOMA-IR)
Baseline fasting glucose (mmol/L) was measured locally whereas
fasting serum insulin (mU/L, Architect Insulin, Abbott, Abbott
Park, IL) was analyzed on frozen samples at the central laboratory.
HOMA-IR was calculated using the formula: (Glucose6Insulin)/
22.5 [17]. It should be noted that a standardized reference range is
lacking for HOMA-IR [18].
Interferon a2a drug concentration
Plasma concentration of interferon-a2a was measured at day 3,
7( i.e. immediately before the second dose of peginterferon-a2a)
and 29. All samples were collected using PPT-tubes, frozen
(270uC), and subsequently analyzed at a central laboratory.
Quantification was performed using 20 ml plasma (diluted 1:5) on
a solid-phase ELISA using high absorbant plates coated with
interferon alfa antibody (AMS Biotechnology Ltd., Oxon, UK).
The detection limit of the assay was 400 pg/mL.
Ribavirin concentration
Plasma samples for ribavirin drug concentration measurement
were drawn immediately before the morning dose of ribavirin at
day 29 (week 4) and at week 12, i.e. trough concentrations. Plasma
ribavirin concentrations were measured by use of solid phase
extraction and high-performance liquid chromatography (HPLC;
Merck-Hitachi, Tokyo, Japan) followed by UV-detection (wave-
length 215 nm).
Liver biopsies
Liver biopsies were obtained from all patients within 24 months
prior to study entry. The evaluation was performed in a blinded
fashion by two independent observers according to the Ishak
protocol [19]. In addition, steatosis was graded as follows:
absent=0, less than 30% of hepatocytes involved=1, 30–70%
of hepatocytes involved=2, and more than 70% of hepatocytes
involved=3 [20].
Statistical methods
Wilcoxon-Mann-Whitney U-test, Kruskal-Wallis test, Chi
squared (x
2) test, and Spearman’s rank correlation coefficient (rs)
test was utilized to evaluate relationships between variables. After
univariate analyses, multivariate analyses were performed on the
per-protocol patients treated for 24 weeks with all variables
associated with the endpoint (P,0.1) being entered. The variables
entered in the multivariate analyses were age, BMI, Ishak fibrosis
stage, steatosis grade, HOMA score, peg-interferon concentrations
on day 3, 7 and 29, ribavirin concentrations day 29 and week 12,
and baseline HCV RNA level. All statistical analyses were
performed using SPSS (version19.0) and StatView (version 5.0,
SAS Institute Inc., Cary, NC, USA). All reported p-values are two-
sided, and p-values,0.05 were considered significant.
Ethical considerations
Written informed consent was obtained from each participating
patient. Ethics committees in each participating country approved
the study (i.e. Regional Ethical Review Board, Gothenburg,
Sweden (Regionala etikpro ¨vningsna ¨mnden i Go ¨teborg), Regional
Committee for Ethics in Medical Research, Bergen, Norway
(Regionaletisk komite for medisinsk og helsefaglig forskning i
Bergen), The Scientific Ethical Committee for the Region of
Middle Jylland, Viborg, Denmark (Den Videnskabsetiske Komite ´
for Region Midtjylland), The Scientific Ethical Committee for the
Region of South Denmark, Vejle, Denmark (Den Videnskabse-
tiske Komite ´ for Region Syddanmark), and the Ethics Committee,
Department of Medicine for the Hospital District of Helsinki and
Uusimaa, Finland (Etiska kommitte ´n fo ¨r inva ¨rtesmedicin)). The
study has been registered at the NIH trial registry (Clinical-
Trials.gov Identifier: NCT00143000).
Results
A strong association was noted between liver histopathology and
body mass index (BMI) as well as HOMA-IR with patients having
higher BMI also having higher HOMA-IR (rs=0.31, P,0.0001),
indicative of insulin resistance and more pronounced steatosis and
fibrosis (Figure 1). Spearman’s rank correlation coefficient (rs) test
for correlation between BMI and HOMA-IR was 0.31
(P,0.0001). When grouping according to HCV genotype, the
association between steatosis and BMI remained significant for
both genotypes 2 and 3, as did the correlation between BMI and
HOMA-IR for genotype 3. As expected, patients with BMI
$30 kg/m
2 also had significantly higher systolic and diastolic
blood pressure as well as baseline triglycerides levels (mean 1.5 vs.
1.0 mmol/L BMI $30 vs. ,30 kg/m
2, P=0.0002; Table 1)
indicative of the metabolic syndrome. In contrast BMI was not
associated with IL28B genotype.
Higher BMI was correlated with significantly lower concentra-
tions of interferon as measured on days 3 (rs=20.21, P=0.0006),
7( rs=20.28, P,0.0001), and 29 (rs=20.38, P,0.0001), (asso-
ciation dichotomized for BMI , or $30 kg/m
2 demonstrated in
Figure 2) as well as ribavirin day 29 (rs=20.32, P,0.0001) and
week 12 (rs=20.37, P=0.0002) (association dichotomized for
BMI , or $30 kg/m
2 demonstrated in Figure 3), and these
correlations were significant for both HCV genotype 2 and 3.
Because the first dose of study medication was administered under
the supervision of a study nurse, the lower interferon concentra-
tions noted on days 3 and 7 could not be attributed to poor patient
compliance. Similarly subsequent dosing was monitored by a
patient diary, and only patients having received at least 80% of the
target dose of peginterferon-a2a and at least 80% of the target
dose of ribavirin for at least 80% of the target treatment duration
were included in the analysis. Thus lower adherence to therapy
was unlikely to contribute to the lower concentrations of interferon
and ribavirin measured on day 29, and ribavirin at week 12. It
should be noted that women overall had approximately 10%
higher ribavirin concentrations even when adjusting for weight as
previously reported [21], and that this has previously been
hypothesized to be secondary to a lower erythrocyte particle
concentration noted among women thus allowing for less
erythrocyte-trapping of ribavirin.
Interferon concentrations at all three time-points sampled were
significantly associated with the first phase decline in HCV RNA
(Figure 4) for both HCV genotypes 2 and 3, but not with the
second phase (rs=20.05 and P=0.4, rs=20.022 and P=0.7,
and rs=0.005 and P=0.9 for interferon concentrations on days 3,
7, and 29 respectively); and this association between interferon
concentrations and the first phase decline was independent of
IL28B genotype. In contrast, ribavirin concentrations were not
associated with either the first (rs=0.018 and P=0.8 and
rs=20.018 and P=0.8 for ribavirin concentrations on day 29
and week 12 respectively) or second phase reduction of HCV
RNA (rs=0.018 and P=0.8 and rs=0.042 and P=0.5 for
ribavirin concentrations on day 29 and week 12 respectively).
Somewhat surprisingly higher BMI was correlated with higher
baseline viral load (rs=0.12, P=0.038), and this correlation
became more pronounced while on treatment as exemplified by
treatment day 3 (rs=0.18, P=0.002), day 7 (rs=0.15, P=0.01),
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(rs=0.45, P,0.0001), and week 12 (rs=0.49, P,0.0001). Simi-
larly a non-significant trend towards a smaller first phase decline in
HCV RNA as measured by the reduction from day 0 to 3 (mean
1.66 vs. 1.91 log10 IU/mL BMI $30 vs. ,30 kg/m
2) and second
phase as measured by the reduction from day 8 to 29 (mean 0.79
vs. 0.83 log10 IU/mL per week BMI $30 vs. ,30 kg/m
2).
However, the association noted between higher BMI and higher
HCV RNA levels day 29 was not reflected by the proportion of
patients achieving undetectable HCV RNA, i.e. RVR (20% vs.
18%, BMI $30 vs. ,30 kg/m
2). In contrast, obese patients were
less likely to achieve undetectable HCV RNA week 12 (i.e. cEVR;
Figure 5).
In addition to the effect on viral kinetics, BMI profoundly
affected SVR especially among patients treated for the standard 24
weeks of treatment duration (Figure 5) with only 62% of patients
with BMI $30 kg/m
2 achieving SVR as compared to 89% among
those with BMI ,30 kg/m
2 (P=0.006). This decrease in SVR
was mirrored by increased rates of relapse and non-response for
both HCV genotypes 2 and 3. In univariate analysis of the
population treated for 24 weeks, both peg-interferon and ribavirin
concentration day 29 where significantly associated with SVR
(P=0.01), and in a multivariate analysis, ribavirin concentrations
week 12, peg-interferon concentrations day 29, and baseline HCV
RNA levels were independent predictors of achieving SVR
(Table 2). Among patients treated for 12 weeks, those achieving
SVR had significantly lower BMI than those that did not (mean
25.5 vs. 27.2 kg/m
2; P=0.02).
Discussion
In spite of the pending introduction of direct antiviral agents
(DAA) in routine clinical practice for HCV genotype 1, few of the
Figure 1. Impact of BMI on baseline histopathology and HOMA-IR. Box plots displaying the 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles of BMI
among patients grouped by steatosis grade (A; n=279) and fibrosis stage (B; n=279), as well as HOMA-IR among patients grouped according to BMI
(C; n=268). P-values obtained using Kruskal-Wallis test.
doi:10.1371/journal.pone.0037521.g001
Figure 2. Impact of obesity on interferon concentrations. Box plots displaying the 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles of the plasma
concentrations of peginterferon (pg/mL) treatment day 3, 7, and 29 (A–C respectively). P-values obtained using Mann-Whitney U-test.
doi:10.1371/journal.pone.0037521.g002
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interferon-a and ribavirin are likely to retain pivotal roles in the
management of chronic HCV genotype 2/3 infection, and a fixed
dose of 800 mg/day ribavirin in conjunction with fixed 180 mg
dosing of peginterferon-a2a [6] or weight-adjusted dosing of
peginterferon-a2b [22] currently is the standard of care for these
viral genotypes. In this setting, the main finding in the present
study was that higher BMI was associated with significantly lower
concentrations of ribavirin and interferon as well as poorer
outcome following fixed dosing of ribavirin and peginterferon-a2a,
that lower plasma concentrations of interferon were associated
with a poorer first phase reduction in HCV RNA, and that both
ribavirin and interferon concentrations along with baseline viral
load were independent predictors of SVR.
The lower bioavailability of peginterferon noted in our study
corroborates the findings reported by Lam et al. (among 11 HCV
infected patients, 6 obese and 5 non-obese) who reported a non-
significant trend towards lower interferon concentrations and
higher baseline viral load following a single dose of 10 mIU of
unpegylated interferon-a2b without the addition of ribavirin
among obese patients. Interestingly in contrast to the present
study, no difference in the first phase decline in HCV RNA was
noted though the sample size was small [15].
The finding in the present study that patients with BMI
$30 kg/m
2 had significantly lower concentrations of ribavirin
following fixed dosing of 800 mg ribavirin/day is not surprising,
and may substantiate the report by Pattullo et al. that weight based
dosing of ribavirin may negate the influence of BMI and weight on
outcome [23]. However, this latter study had only a limited
number of patients infected with genotypes 2 (n=22) or 3 (n=31),
and a substantial proportion of patients received weight based
dosing of peginterferon-a2b. Fried et al. noted that among difficult-
to-cure (i.e. body weight .85 kg and viral load .800,000 IU/mL)
HCV genotype 1 infected patients higher fixed doses of both
ribavirin (1600 mg daily) and peginterferon-a2a (270 mg/week)
improved viral kinetics and SVR rates as compared to lower doses
of ribavirin (1200 mg daily) and peginterferon-a2a (180 mg/week)
[24]. This is in contrast to the PROGRESS study where no benefit
was noted from giving 1400/1600 mg ribavirin daily as compared
to 1200 mg in an intention-to-treat analysis among difficult-to-
treat (i.e. body weight $85 kg and viral load $400,000 IU/mL)
HCV genotype 1 infected patients [25]. It should be noted,
however, that 42% of these patients had a BMI below 30 kg/m
2,
and no subset analysis restricted to patients with BMI $30 kg/m
2
has yet been reported. Additionally in a per-protocol analysis
restricted to patients with at least 80% exposure to the planned
ribavirin dose, numerically higher SVR rates were obtained with
intensified regimens suggesting that such strategies may be
successful if tolerated [25].
Figure 3. Impact of obesity on ribavirin concentrations. Box plots displaying the 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles of the plasma
concentrations of ribavirin (mg/mL) treatment day 29 and week 12 (A and B respectively). P-values obtained using Mann-Whitney U-test.
doi:10.1371/journal.pone.0037521.g003
Figure 4. Impact of interferon concentration on first phase
decline in HCV RNA. Correlation between the plasma concentration
of peginterferon (pg/mL) treatment day 3 and decline in HCV RNA
(log10 IU/mL) between baseline and treatment day 3 of combination
therapy evaluated by use of Spearman’s rank correlation coefficient rs
test.
doi:10.1371/journal.pone.0037521.g004
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m
2 may benefit from increased dosing of interferon, which is
substantiated by the abovementioned study by Fried et al. [24].
However, in the PROGRESS study no significant differences in
SVR were noted in patients weighing $85 kg receiving a 12-week
induction regime of 360 mg peginterferon-a2a weekly as compared
to standard dosing in an intention-to-treat analysis [25]. However,
whentheanalysiswasrestrictedtopatientstoleratingatleast80%of
the planned interferon dosing, numerically higher SVR rates were
achieved with intensified regimens reiterating the importance of
adherence [25]. Additionally the potential benefit of exposure to
higher doses of interferon beyond 12 weeks of therapy was not
investigated in this latter study. Similarly, in the IDEAL study, no
significant difference in SVR was noted among patients with higher
weight regardless whether they received weight based dosing of
peginterferon-a2b or a fixed 180 mg dosing of peginterferon-a2a
although a non-significant trend towards slightly higher SVR rates
was noted in patients weighing between 105 and 125 kg who
received weight based dosing of interferon (44.9%, 42.1%, and
38.9% for peginterferon-a2b 1.0 and 1.5 mg/kg body weight and
180 mg peginterferon-a2a respectively) [26]. However, it should be
noted that in this weight class patients treated with peginterferon-
a2b received 1400 mg ribavirin daily as opposed to 1200 mg daily
forpatientstreatedwithpeginterferon-a2a,andthuslowerribavirin
dosing may have contributed to the lower numerical SVR rates
noted following fixed interferon dosing.
In addition to differences in bioavailability of interferon and
ribavirin, we also noted that patients with higher BMI had higher
baseline viral load, more pronounced steatosis, in addition to
features of the metabolic syndrome as previously reported, e.g.
higher systolic and diastolic blood pressure, higher HOMA-IR,
and higher baseline triglyceride levels. Although weight reduction
among obese HCV patients is known to normalize many aspects of
the metabolic syndrome as well as liver histology [27,28] and thus
is likely to have a beneficial impact on combination therapy for
HCV, this cannot be addressed in the present study. Similarly
whether increased treatment duration beyond 24 weeks for
patients with BMI $30 kg/m
2 would improve outcome is outside
the scope of this study. Since replication, assembly and release of
HCV occurs in close proximity to intracellular lipid droplets [29],
the finding of a higher baseline viral load among obese patients,
hypothetically, may be secondary to the elevated pre-treatment
plasma triglyceride levels or to more advanced steatosis.
In conclusion, higher BMI is associated with lower bioavail-
ability of both peginterferon and ribavirin, which subsequently
along with higher baseline viral load are dominant risk factors for
treatment failure in obese patients with chronic HCV genotypes 2
and 3 infection.
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